EPRX News & Events

Eupraxia Pharmaceuticals announced positive symptom data from patients in the two highest dose cohorts from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. Sub-analyses of scores including at least 12 injections indicated that: at 12 weeks, 59% of patients achieved clinical remission; at 24 weeks, 76% of patients maintained clinical remission, and at 52 weeks, 67% of patients maintained clinical remission. At 24 weeks, dose cohort 9 showed a mean reduction of 4.0 points in SDI score where a reduction of 3.0 points is considered clinical remission. Comparison of histologic and symptom data from Cohort 8b versus Cohort 8 at 12 weeks demonstrated meaningfully improved outcomes due to improved drug delivery to the tissues associated with the appropriate catheter. No SAEs have been reported to date. EP-104GI has been well tolerated at all dose levels, including the highest dose of 8 mg/site.

Cantor Fitzgerald and LifeSci Capital acted as joint book running managers for the offering.

Eupraxia Pharmaceuticals announced the company has filed a preliminary prospectus supplement to its short form base shelf prospectus dated February 5, 2024 in connection with a proposed public offering of common shares of the company. Cantor and LifeSci Capital are acting as joint book-running managers for the offering. Bloom Burton is also acting as co-manager for the offering.